Bowel perforation related with ipilimumab.

Andrea Robayo; Marcela Mejía; Andrés Felipe Cardona; Henry Becerra; Jorge Miguel Otero; Hernán Carranza; Carlos Vargas; Javier Carrera

doi:10.51643/22562915.290

Bowel perforation related with ipilimumab.

Perforación intestinal relacionada con ipilimumab.

Published 2012-04-01

Open | Download

PDF (Spanish) FLIP

How to Cite

1.

Robayo A, Mejía M, Cardona AF, Becerra H, Otero JM, Carranza H, et al. Bowel perforation related with ipilimumab. Rev. colomb. hematol. oncol. [Internet]. 2012 Apr. 1 [cited 2025 Dec. 5];1(1):67-9. https://doi.org/10.51643/22562915.290

Download Citation

Citations

Citations in Crossref

Citations in Scopus

Google Sholar Citation

Issue

Vol. 1 No. 1 (2012): Abril

Section

Images in hematology and oncology

How to Cite

1.

Robayo A, Mejía M, Cardona AF, Becerra H, Otero JM, Carranza H, et al. Bowel perforation related with ipilimumab. Rev. colomb. hematol. oncol. [Internet]. 2012 Apr. 1 [cited 2025 Dec. 5];1(1):67-9. https://doi.org/10.51643/22562915.290

DOI

https://doi.org/10.51643/22562915.290

Dimensions

PlumX

license

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Andrea Robayo

Fundación Santa Fe de Bogotá

Marcela Mejía

Fundación Santa Fe de Bogotá

Andrés Felipe Cardona

Fundación Santa Fe de Bogotá

Henry Becerra

Fundación Santa Fe de Bogotá

Jorge Miguel Otero

Fundación Santa Fe de Bogotá

Show authors biography

Andrea Robayo,

Medicine Faculty, Universidad de los Andes, Hospital Universitario Fundación Santa Fe de Bogotá (Bogotá, Colombia).

Marcela Mejía,

Laboratory and Pathology Department, Fundación Santa Fe de Bogotá (Bogotá, Colombia).

Andrés Felipe Cardona,

Clinical and Translational Oncology Group, Institute of Oncology, Fundación Santa Fe de Bogotá (Bogotá, Colombia). Foundation for Clinical and Applied Cancer Research (FICMAC); associated researcher ONCOLGroup.

Henry Becerra,

Clinical and Translational Oncology Group, Institute of Oncology, Fundación Santa Fe de Bogotá (Bogotá, Colombia).

Jorge Miguel Otero,

Clinical and Translational Oncology Group, Institute of Oncology, Fundación Santa Fe de Bogotá (Bogotá, Colombia). Foundation for Clinical and Applied Cancer Research (FICMAC); associated researcher ONCOLGroup.

Hernán Carranza,

Clinical and Translational Oncology Group, Institute of Oncology, Fundación Santa Fe de Bogotá (Bogotá, Colombia). Foundation for Clinical and Applied Cancer Research (FICMAC); associated researcher ONCOLGroup.

Carlos Vargas,

Clinical and Translational Oncology Group, Institute of Oncology, Fundación Santa Fe de Bogotá (Bogotá, Colombia). Foundation for Clinical and Applied Cancer Research (FICMAC); associated researcher ONCOLGroup.

Javier Carrera,

Colon and Rectal Surgery Department, Fundación Santa Fe de Bogotá (Bogotá, Colombia).

A 48-year-old man was admitted to hospital following four days of having suffered diarrhea and a febrile episode on the same day as he consulted. The diarrhea had increased to 6 episodes during the 12 hours before admission, regardless of the administration of loperamide or low doses of dexamethasone. He referred to no other symptoms upon admission.

Article visits 168 | PDF visits 124